HEARD (Long Term) Study - Histology of the Esophagus in Acid-Related Disease
Sponsor
AstraZeneca (Industry)
Overall Status
Completed
CT.gov ID
NCT00243724
Collaborator
(none)
350
10
26
35
1.3
Study Details
Study Description
Brief Summary
Determine if different levels of acid-suppression with esomeprazole for 6 months on chosen histological markers of esophageal epithelial acid-related disease in patients with upper GI symptoms.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 3 |
Study Design
Study Type:
Interventional
Anticipated Enrollment
:
350 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
An Open-Label, Parallel-Group, Multi-Centre Study to Determine the Effect of Treatment With Esomeprazole for Six Months on Histological Markers of Esophageal Epithelial Acid-Related Disease in Patients With Upper GI Symptoms.
Study Start Date
:
Apr 1, 2005
Actual Primary Completion Date
:
Jun 1, 2007
Actual Study Completion Date
:
Jun 1, 2007
Outcome Measures
Primary Outcome Measures
- Change from baseline after 6 months in the level of ki-67 expression and histological markers of esophageal epithelial acid-related disease after acid-suppressive therapy with esomeprazole []
Secondary Outcome Measures
- Changes in immunohistochemical markers of esophageal epithelial acid-related disease after 6 months treatment with different levels of acid suppression with esomeprazole []
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
Signed informed consent
-
18 years or older
-
history of upper GI symptoms
Exclusion Criteria:
-
Peptic ulcer disease
-
upper gastrointestinal surgery
-
malignancy
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Research Site | Vancouver | British Columbia | Canada | |
2 | Research Site | Halifax | Nova Scotia | Canada | |
3 | Research Site | Guelph | Ontario | Canada | |
4 | Research Site | Hamilton | Ontario | Canada | |
5 | Research Site | Kingston | Ontario | Canada | |
6 | Research Site | Mississauga | Ontario | Canada | |
7 | Research Site | North York | Ontario | Canada | |
8 | Research Site | Montreal | Quebec | Canada | |
9 | Research Site | Pointe-Claire | Quebec | Canada | |
10 | Research Site | Quebec | Canada |
Sponsors and Collaborators
- AstraZeneca
Investigators
- Study Director: AstraZeneca Canada Medical Director, MD, AstraZeneca
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00243724
Other Study ID Numbers:
- D9612L00078
First Posted:
Oct 25, 2005
Last Update Posted:
Mar 26, 2009
Last Verified:
Mar 1, 2009
Keywords provided by ,
,
Additional relevant MeSH terms: